l   [発端となった論文]Unexpected mutations after CRISPR-Cas9 editing in vivo. Schaefer KA, Wu WH, Colgan DF, Tsang SH, Bassuk AG, Mahajan VB. (Stanford U & Iowaw U) Nat Methods. 2017 May 30;14(6):547-548

²  (要約)RD1マウスPde6b遺伝的;WGSタをコントロWGS及びdbSNP/MGP DB配列と比、既存オフタゲット解析ソフトで予されない新規変異(特にSNVs)多数同定;

²  【注】CRISPR Cas9の応用(特に、臨床応用)に不安をいただかせる報告であり、株式市場は直ちにCRISPR技術関連企業株安で反応

l   [CRISPR関連企業・研究者からの反論・反証]

²  Gene-Editing Companies Hit Back at Paper That Criticized CRISPR. Regalado A. MIT Technol Rev. June 9, 2017

²  Questioning unexpected CRISPR off-target mutations in vivo. Kim ST Kim JS. bioRxiv Posted June 30, 2017

²  “Unexpected mutations after CRISPR-Cas9 editing in vivo”are most likely pre-existing sequence variants and not nuclease-induced mutations. Lareau C, Clement K, Hsu JY, Pattanayak V, Joung JK, Aryee MJ, Pinello L. bioRxiv Posted July 5, 2017.

²  A reanalysis of Schaefer et al. does not indicate extensive CRISPR/Cas9 mediated off-target editing. Lescarbeau RM, Murray BA, Barnes TM, Bermingham N. bioRxiv Posted July 6, 2017.

²  CRISPR gene editing technique is probably safe, study confirms. Michael Le Page. New Scientist 6 July 2017.